×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MIRM – mirum pharmaceuticals, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MIRM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/27
08:41 am
mirm
LIVMARLI Now Approved in Japan for ALGS and PFIC [Yahoo! Finance]
Low
Report
LIVMARLI Now Approved in Japan for ALGS and PFIC [Yahoo! Finance]
3/27
08:30 am
mirm
LIVMARLI Now Approved in Japan for ALGS and PFIC
Low
Report
LIVMARLI Now Approved in Japan for ALGS and PFIC
3/24
05:20 pm
mirm
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call [Seeking Alpha]
Low
Report
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call [Seeking Alpha]
3/21
08:09 pm
mirm
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe [Yahoo! Finance]
Low
Report
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe [Yahoo! Finance]
3/10
08:00 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/1
07:07 pm
mirm
Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report [Yahoo! Finance]
Medium
Report
Analyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year Report [Yahoo! Finance]
2/28
08:13 am
mirm
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at HC Wainwright from $66.00 to $72.00. They now have a "buy" rating on the stock.
Low
Report
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its price target raised by analysts at HC Wainwright from $66.00 to $72.00. They now have a "buy" rating on the stock.
2/27
11:16 am
mirm
Q4 2024 Mirum Pharmaceuticals Inc Earnings Call [Yahoo! Finance]
Low
Report
Q4 2024 Mirum Pharmaceuticals Inc Earnings Call [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
08:00 am
mirm
mirum pharmaceuticals, inc. - common stock
BEAT
Report
0.5%
mirum pharmaceuticals, inc. - common stock
8/7/2024
04:01 pm
mirm
mirum pharmaceuticals, inc. - common stock
MISS
Report
2.3%
mirum pharmaceuticals, inc. - common stock
5/8/2024
04:02 pm
mirm
mirum pharmaceuticals, inc. - common stock
MISS
Report
3.2%
mirum pharmaceuticals, inc. - common stock
Date
Time
Symbol
Headline
Impact
3/19
05:40 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Mar 18 Filed by: Howe Jolanda
Low
Report
Form 4 Mirum Pharmaceuticals, For: Mar 18 Filed by: Howe Jolanda
3/18
09:30 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Peetz Christopher
Medium
Report
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Peetz Christopher
3/18
09:30 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Radovich Peter
Medium
Report
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Radovich Peter
3/18
09:30 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Howe Jolanda
Medium
Report
Form 4 Mirum Pharmaceuticals, For: Mar 15 Filed by: Howe Jolanda
3/18
05:04 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Mar 14 Filed by: Heron Patrick J
Medium
Report
Form 4 Mirum Pharmaceuticals, For: Mar 14 Filed by: Heron Patrick J
3/18
04:13 pm
mirm
Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda
Medium
Report
Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda
3/17
04:21 pm
mirm
Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda
Low
Report
Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda
3/12
04:51 pm
mirm
Form 4 Mirum Pharmaceuticals, For: Mar 10 Filed by: Heron Patrick J
Low
Report
Form 4 Mirum Pharmaceuticals, For: Mar 10 Filed by: Heron Patrick J
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/13
Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast
111.0%
3/23 Form 4 Mirum Pharmaceuticals, For: Mar 19 Filed by: Tucker Edwin Jonathan 20.8%
3/12 Form 10-K Mirum Pharmaceuticals, For: Dec 31 16.2%
1/16 Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund 15.2%
12/7 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
4/17 Mirum Pharmaceuticals (NASDAQ: MIRM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/28 Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer 5.5%
4/30 Form 3 Mirum Pharmaceuticals, For: Apr 28 Filed by: Radovich Peter 5.4%
2/18 Mirum Pharmaceuticals to Participate at Four Upcoming Conferences 5.0%
4/9 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 4.7%
3/23 Form 4 Mirum Pharmaceuticals, For: Mar 19 Filed by: Tucker Edwin Jonathan 20.8%
3/12 Form 10-K Mirum Pharmaceuticals, For: Dec 31 16.2%
1/16 Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund 15.2%
12/7 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%
4/17 Mirum Pharmaceuticals (NASDAQ: MIRM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/28 Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer 5.5%
4/30 Form 3 Mirum Pharmaceuticals, For: Apr 28 Filed by: Radovich Peter 5.4%
2/18 Mirum Pharmaceuticals to Participate at Four Upcoming Conferences 5.0%
4/9 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. 4.7%
TOP News Decliners
3/17
Mirum Pharmaceuticals (MIRM) Investor Presentation - Slideshow [Seeking Alpha]
-10.7%
1/8 Mirum Pharmaceuticals Announces Pricing of Public Offering -6.6%
1/6 Form S-1 Mirum Pharmaceuticals, -6.0%
12/17 Mirum Pharmaceuticals (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc from $21.00 to $30.00. They now have a "buy" rating on the stock. -5.8%
4/16 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.6%
1/9 Form 424B4 Mirum Pharmaceuticals, -5.0%
8/28 Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update -4.8%
8/12 Mirum Pharmaceuticals (NASDAQ: MIRM) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -4.6%
12/28 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.4%
9/26 Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference -3.9%
1/8 Mirum Pharmaceuticals Announces Pricing of Public Offering -6.6%
1/6 Form S-1 Mirum Pharmaceuticals, -6.0%
12/17 Mirum Pharmaceuticals (NASDAQ: MIRM) had its price target raised by analysts at Citigroup Inc from $21.00 to $30.00. They now have a "buy" rating on the stock. -5.8%
4/16 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.6%
1/9 Form 424B4 Mirum Pharmaceuticals, -5.0%
8/28 Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update -4.8%
8/12 Mirum Pharmaceuticals (NASDAQ: MIRM) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -4.6%
12/28 Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.4%
9/26 Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: